DEF 14A: Galecto Seeks Shareholder Nod for Cayman Move, Equity Plans

Galecto, Inc. is calling a special meeting to approve a redomestication to the Cayman Islands, increase authorized common stock, and establish new equity incentive plans following its Damora acquisition and $285 million financing.

Summary

• A special meeting of stockholders is scheduled for February 9, 2026, to vote on six key proposals.
• Proposal No. 1 seeks approval for the issuance of common stock upon conversion of Series B and Series C Non-Voting Convertible Preferred Stock, issued in connection with the Damora acquisition and a concurrent $285 million PIPE financing.
• Proposal No. 2 requests an increase in authorized common stock from 300,000,000 to 500,000,000 shares.
• Proposal No. 3 involves the redomestication of the company from Delaware to the Cayman Islands, aiming for substantial savings on annual Delaware franchise tax (estimated $200,000 for fiscal year 2026) and greater flexibility in corporate transactions.
• Proposal No. 4 is for the approval of the Galecto, Inc. 2026 Equity Incentive Plan, with an initial share pool of 9,299,832 shares, increasing annually by 5% of diluted stock.
• Proposal No. 5 is for the approval of the Galecto, Inc. 2026 Employee Stock Purchase Plan, with an initial share pool of 619,989 shares, increasing annually by the lesser of 1,000,000 shares or 1% of diluted stock.
• Proposal No. 6 is to approve the adjournment or postponement of the Special Meeting, if necessary, to solicit additional votes.
• The company acquired Damora Therapeutics, Inc. in November 2025, a stock-for-stock transaction that included 265,309 shares of Common Stock, 16,366 shares of Series B Preferred Stock, and 4,241 shares of Series C Preferred Stock, plus assumption of 434,508 stock options.
• The concurrent PIPE investment raised approximately $285 million through the issuance of 39,641 shares of Series C Preferred Stock at $7,186.90 per share (or $7.19 per share on an as-converted basis).
• Post-transactions, legacy stockholders retained approximately 2.4% of the combined company, Damora stockholders received 33.7%, and PIPE investors received 63.9% on an as-converted-to-Common Stock basis (excluding options and RSUs).
• The company's pipeline includes DMR-001 (targeting mutCALR-driven MPNs), DMR-002, DMR-003 (additional anti-mutCALR therapies), and GB3226 (a dual inhibitor for AML).
• Preclinical studies for DMR-001 showed approximately three-fold greater inhibition of Type 1 mutCALR-dependent cell proliferation and ten-fold greater inhibition for Type 2 mutCALR compared to a reference antibody.
• DMR-001 also demonstrated a five-fold longer half-life in non-human primates compared to a reference mutCALR antibody without half-life extending modifications.
• The company expects to finalize the DMR-001 license agreement in Q1 2026 and file an IND for DMR-001 in mid-2026, initiating a Phase 1 trial in ET and MF patients with a subcutaneous formulation.
• IND filings for DMR-002 are anticipated in H2 2026, for DMR-003 in 2027, and for GB3226 in AML patients in Q1 2026.
• As of November 30, 2025, the company had $274 million in cash and cash equivalents, expected to fund operations into 2029.

Sentiment

Score: 7

Explanation: The filing outlines significant strategic moves including a major acquisition and substantial capital raise, which are strong positives for a clinical-stage biotech. The preclinical data for pipeline candidates is promising, and the redomestication offers clear financial and governance benefits. However, the inherent risks of drug development, future capital needs, and significant shareholder dilution temper the overall sentiment, preventing a 'strong buy' score.

Positives

• The Damora acquisition significantly bolsters the pipeline with three new product candidates (DMR-001, DMR-002, DMR-003) targeting Myeloproliferative Neoplasms (MPNs) and Acute Myeloid Leukemia (AML).
• A concurrent PIPE investment raised approximately $285 million, providing substantial capital to fund near-term development of the expanded pipeline.
• DMR-001, the lead product candidate, demonstrated superior preclinical potency (3x for Type 1, 10x for Type 2 mutCALR) and a 5x longer half-life in NHPs compared to a reference antibody, suggesting potential for a best-in-class therapy with convenient subcutaneous dosing.
• The redomestication to the Cayman Islands is expected to result in substantial long-term savings on annual Delaware franchise tax (estimated $200,000 for fiscal year 2026).
• The redomestication may reduce the risk of opportunistic stockholder demands and litigation, allowing management to focus on business operations.
• The redomestication is expected to provide greater protection for directors and officers, potentially aiding in attracting and retaining qualified management personnel.
• The 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan are designed to attract and retain key talent by aligning employee interests with stockholders.
• The company has a strong management team and investor syndicate, including Fairmount Funds Management LLC, Viking Global Investors, and Venrock Healthcare Capital Partners.

Negatives

• The Damora acquisition resulted in significant dilution for legacy stockholders, who now retain approximately 2.4% of the combined company on an as-converted basis (excluding options and RSUs).
• The Series B Preferred Stock holders have significant approval rights, including over fundamental transactions, board size increases, and retention/replacement of key advisors, which could delay or prevent certain corporate actions.
• Failure to obtain stockholder approval for the conversion of Series B and Series C Preferred Stock could require the company to settle these shares in cash, materially harming operations and potentially raising going concern doubts.
• The company has a limited operating history and no products approved for commercial sale, making future success and viability difficult to assess.
• The company expects to continue incurring losses for the foreseeable future and will require substantial additional capital beyond the current cash runway into 2029.
• The target patient population for MPNs is small and not definitively determined, which could limit potential revenues if estimates are inaccurate.
• The approach to developing DMR-001, DMR-002, and DMR-003 using half-life extension technologies and enhanced binding affinity is unproven in humans, and preclinical results may not translate to clinical success.
• The company relies heavily on third parties for preclinical studies, clinical trials, and manufacturing, introducing risks related to performance, compliance, and supply chain disruptions.
• Geopolitical instability and U.S. legislation (e.g., BIOSECURE Act) could impact relationships with foreign CMOs like WuXi Biologics (Hong Kong), potentially causing delays or increased costs.
• The company's intellectual property portfolio is at an early stage, with no owned or licensed patents for DMR-001, DMR-002, or DMR-003 currently issued, exposing it to competitive risks.
• The market price of common stock is expected to remain volatile due to various factors, including clinical trial results, competition, and financing needs.

Risks

• No guarantee that the acquisition of Damora will increase stockholder value, and significant integration challenges could result in management and business disruptions.
• Limited operating history and no products approved for commercial sale make it difficult to evaluate current business and likelihood of success.
• Substantial additional capital will be required to finance future operations; inability to raise capital may force delays, reductions, or elimination of research programs or commercialization efforts.
• Expectation to continue incurring losses for the foreseeable future; may never achieve or sustain profitability.
• Competition from entities with greater financial resources and expertise in drug development and commercialization.
• Programs are in preclinical stages of development and may fail or suffer delays, materially and adversely affecting viability.
• Substantial dependence on the success of DMR-001; future clinical trials may not be successful.
• Unproven approach to discovery and development of DMR-001, DMR-002, and DMR-003; may not build a pipeline with commercial value.
• Lengthy and expensive preclinical and clinical development process with uncertain outcomes; earlier results may not be predictive of future trials.
• Difficulties in enrolling patients in clinical trials, especially given small patient populations for MPNs and competition from approved therapies or other trials.
• Preliminary, topline, or interim data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Future clinical trials may reveal significant adverse events or undesirable side effects, halting development, inhibiting regulatory approval, or limiting commercial potential.
• Expenditure of limited resources on a particular program may lead to failure to capitalize on more profitable opportunities.
• Approved products may not achieve adequate market acceptance among clinicians, patients, and payors.
• Certain programs may compete with other internal programs, negatively impacting business and future revenue.
• FDA may not accept data from clinical trials conducted outside the United States, requiring additional costly and time-consuming trials.
• Reliance on collaborations and licensing arrangements with third parties (e.g., Paragon, Rockefeller University); failure to maintain or successful execution of these could negatively impact business.
• Reliance on third parties (CROs, CMOs) to conduct preclinical studies and clinical trials; failure to properly carry out duties or meet deadlines could delay or prevent regulatory approval.
• Reliance on third-party CMOs for manufacturing; inability to use facilities or production difficulties could adversely affect business.
• Need to grow the size of the organization to implement plans and strategies, which may lead to management difficulties.
• Intellectual property portfolio is at an early stage; uncertainty in obtaining and protecting patent rights exposes the company to loss of competitive advantage.
• Subject to intellectual property lawsuits or need to file lawsuits to protect IP, resulting in substantial costs and liability.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; delays or failure to obtain approvals will materially impair revenue generation.
• Inability to meet chemistry, manufacturing, and control requirements could prevent product approval.
• Product candidates approved as biologics may face competition from biosimilars sooner than anticipated.
• Extensive ongoing regulatory obligations and review post-approval, potentially leading to significant additional expense or penalties for non-compliance.
• Disruptions at government agencies (FDA, SEC) due to funding shortages or global health concerns could hinder timely review and approval.
• Exposure to costly and damaging liability claims during clinical or commercial stages; product liability insurance may not cover all damages.
• Adverse legislative or regulatory tax changes could negatively impact financial condition.
• Acquisition of businesses or formation of strategic alliances may not realize expected benefits.
• Cash held at financial institutions may exceed federally-insured limits, posing a risk of loss or delayed access in case of bank failure.
• Changes to patent laws in the United States and other jurisdictions could diminish the value of patents.
• Failure to identify relevant third-party patents or incorrect interpretation of patent scope could adversely affect ability to develop and market products.
• Claims challenging inventorship or ownership of patents could lead to loss of valuable intellectual property rights.
• Licensed technology may be subject to retained rights by licensors, potentially leading to competition.
• Geopolitical instability and trade restrictions (e.g., BIOSECURE Act) could impact foreign CMOs and supply chain.
• Business operations and arrangements with healthcare professionals are subject to fraud and abuse laws, potentially leading to penalties.
• Stringent and changing laws relating to privacy, data protection, and data security could lead to enforcement actions, fines, and litigation.
• Unfavorable pricing regulations and third-party coverage/reimbursement policies could prevent competitive pricing and harm business.
• Difficulties from healthcare and regulatory legislative reform measures, including those impacting drug pricing.
• Inability to obtain accelerated approval could increase clinical trial duration and cost, delaying regulatory approvals.
• Market price of common stock is expected to be volatile.
• Delaware law and corporate governance provisions have anti-takeover implications.
• Exclusive forum provisions in Certificate of Incorporation and Bylaws may limit stockholders' ability to choose a judicial forum.
• Additional costs and demands on management from complying with public company laws and regulations.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements.
• No anticipation of cash dividends in the foreseeable future; capital appreciation is the sole source of gain for stockholders.
• Future sales of shares by existing stockholders could cause stock price to decline.
• Executive officers, directors, and principal stockholders have the ability to control or significantly influence matters submitted for stockholder approval.
• Conflicts of interest may arise between the company and related parties (Paragon, Fairmount, Paramora).
• If equity research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Ability to use net operating loss (NOL) carryforwards and other tax attributes may be limited due to ownership changes.

Future Outlook

The company expects its existing cash and cash equivalents of $274 million (as of November 30, 2025) to fund operating expenses and capital expenditure requirements into 2029. It intends to file an Investigational New Drug (IND) application for DMR-001 in mid-2026, initiating a Phase 1 trial in ET and MF patients. IND filings for DMR-002 are anticipated in the second half of 2026, for DMR-003 in 2027, and for GB3226 in AML patients in the first quarter of 2026. The company aims to develop a portfolio of targeted mutation-directed candidates to address the full spectrum of MPN disease and believes GB3226 has the potential to treat a broad portion of the AML patient population.

Management Comments

• The Board of Directors believes that the Cayman Redomestication is in the best interests of the Company and our stockholders, as it will eliminate the annual Delaware franchise tax, potentially reduce the risk of opportunistic stockholder demands and litigation, and provide greater protection for directors and officers.
• The Board of Directors believes that the Cayman Redomestication will give us more flexibility and predictability in various corporation transactions.
• The Board of Directors believed that the Asset Acquisition was more favorable to our stockholders than the potential value that might have resulted from other options available to us, including a potential liquidation or dissolution of the Company.
• The Board of Directors believes we were able to increase the implied value to our stockholders by preserving cash that otherwise would have been spent continuing to operate the business under the more elongated closing process of the Traditional Structure (for the Damora acquisition).
• Following the Financing, we believe we have adequate resources to fund the near-term development of GB3226 and the research programs under the Paragon Option Agreement, subject to our exercise of the Option with respect to such research programs.
• We believe that DMR-001 has the potential to become a best-in-class anti-mutCALR therapy due to two differentiating features compared to marketed therapies and therapies in development: increased potency and longer half-life.
• We believe that GB3226 can overcome some of the limitations of existing AML therapies through its ability to simultaneously inhibit two targets that are key drivers of AML.

Industry Context

Galecto operates in the highly competitive biopharmaceutical industry, specifically targeting hematological malignancies like Myeloproliferative Neoplasms (MPNs) and Acute Myeloid Leukemia (AML). The company's strategy involves developing next-generation antibodies and small molecule inhibitors, leveraging advanced antibody engineering for improved potency and pharmacokinetics. This positions Galecto against multinational biopharmaceutical companies, specialized biotechnology firms, and academic institutions with significantly greater resources. The focus on targeted therapies for specific genetic mutations in MPNs (mutCALR) and AML (ENL YEATS, FLT3) aligns with a broader industry trend towards precision medicine. The market for AML therapies is projected to grow significantly, indicating a substantial opportunity, but also intense competition from existing approved drugs and numerous product candidates in development.

Comparison to Industry Standards

• DMR-001 is designed to improve upon existing anti-mutCALR therapies, such as Incyte's INCA033989, by demonstrating approximately three-fold greater inhibition of Type 1 mutCALR-dependent cell proliferation and ten-fold greater inhibition for Type 2 mutCALR in preclinical studies.
• DMR-001's engineered extended half-life (five-fold longer in NHPs compared to a reference antibody) aims to enable more convenient subcutaneous dosing, potentially less frequently than intravenously administered INCA033989, which is a significant patient benefit for chronic diseases like ET.
• GB3226, a dual inhibitor of ENL YEATS and FLT3, is positioned to offer improved and more durable anti-tumor activity compared to current AML therapies by targeting two key drivers simultaneously, potentially reducing resistance development seen with single-target FLT3 inhibitors like gilteritinib and quizartinib, or menin inhibitors like revumenib.
• The company's preclinical data for GB3226 showed significant improvements in survival in an MV4-11 mouse model compared to gilteritinib and revumenib, suggesting a potentially superior efficacy profile.
• The company's cash runway into 2029, following the $285 million PIPE, provides a longer operational horizon compared to many early-stage biotechs, which often require more frequent capital raises.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any claim or litigation that would individually or in the aggregate be reasonably expected to have a material adverse effect on its business.
• Litigation, regardless of outcome, can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• Fairmount Funds Management LLC (Fairmount) beneficially owns more than 5% of Paragon Therapeutics, Inc. (Paragon) and has contractual rights to approve Paragon's executive officers.
• Paramora Holding LLC (Paramora) is an entity formed by Paragon to hold equity in Damora (and now Galecto) to share profits with certain Paragon employees.
• Paragon and Paramora each beneficially own more than 5% of a class of Galecto's voting securities through Common Stock holdings, though not expected to exceed 5% after Conversion Approval.
• Fairmount beneficially owns 19.99% of Galecto's Common Stock (assuming conversion of Series B and C Preferred Stock, subject to limitations).
• Three of Galecto's directors (Peter Harwin, Christopher Cain, Ph.D., and Julianne Bruno) are affiliated with Fairmount and were appointed in accordance with the Acquisition Agreement.
• Fairmount-managed entities received the same consideration as other investors in the transactions, and Fairmount received Series B Preferred Stock in the Asset Acquisition.
• Ms. Bruno, Paragon, and Paramora received the same consideration as other investors and Damora stockholders in the Asset Acquisition, except Fairmount.
• Conflicts of interest may arise between Galecto and Paragon or Fairmount regarding target selection, option exercise, license agreement negotiations, resource allocation, intellectual property enforcement, and strategic partnerships.
• Galecto's audit committee is responsible for the review, consideration, and approval or ratification of related party transactions.

Stakeholder Impact

• **Shareholders:** Will experience significant dilution from the Damora acquisition and PIPE financing (legacy stockholders retaining 2.4%). Voting power will be affected by the conversion of preferred stock and the redomestication to Cayman Islands law, which alters certain rights and protections. The increase in authorized shares could lead to further dilution. The new equity plans could benefit employees but also dilute existing shareholders.
• **Employees:** Benefit from the new 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, designed to attract and retain talent through stock-based compensation. Management changes include a new CFO and new board members.
• **Customers/Patients:** Potential for new therapies for hematological malignancies (MPNs, AML) through the expanded pipeline (DMR-001, DMR-002, DMR-003, GB3226). Improved dosing convenience for DMR-001 is a potential benefit.
• **Regulatory Authorities:** The company will continue to be subject to extensive regulation by the FDA and comparable foreign authorities, with ongoing compliance requirements for clinical trials, manufacturing, and commercialization. The redomestication will shift governance to Cayman Islands law, but the company will remain a U.S. corporation for tax purposes and continue SEC filings.
• **Creditors:** The $285 million capital raise strengthens the company's financial position, extending its cash runway into 2029, which is positive for creditors. However, the potential for cash settlement of preferred shares if conversion is not approved could create a significant liability.

Next Steps

• Hold a Special Meeting of Stockholders on February 9, 2026, to vote on the Conversion Proposal, Authorized Shares Proposal, Redomestication Proposal, 2026 Equity Incentive Plan Proposal, 2026 Employee Stock Purchase Plan Proposal, and Adjournment Proposal.
• Finalize the DMR-001 license agreement in the first quarter of 2026.
• File an Investigational New Drug (IND) application, or equivalent, for DMR-001 in mid-2026.
• Initiate a Phase 1 trial for DMR-001 in ET and MF patients with a subcutaneous formulation after regulatory approval.
• File an IND or Clinical Trial Notification, or equivalent, for DMR-002 in the second half of 2026.
• File an IND or Clinical Trial Notification, or equivalent, for DMR-003 in 2027.
• File an IND for GB3226 in AML patients in the first quarter of 2026.
• Prepare and file a resale registration statement with the SEC within 45 calendar days following the closing of the Financing, as per the Registration Rights Agreement.
• Paramora will be granted warrants to purchase 1.00% of outstanding capital stock on December 31, 2025, and December 31, 2026.
• The 2026 Equity Plan and 2026 ESPP share pools will automatically increase on January 1 of each year beginning in 2027 and ending with a final increase on January 1, 2036.

Key Dates

Recommendation

Galecto's strategic pivot through the Damora acquisition and the substantial $285 million PIPE financing are significant developments that provide a much-needed capital infusion and an expanded pipeline in hematological oncology. The preclinical data for DMR-001 and GB3226 show promise, suggesting potential for best-in-class therapies. The proposed redomestication to the Cayman Islands offers tangible cost savings and governance flexibility. However, the company remains a clinical-stage biotech with no approved products, facing high development risks, intense competition, and the need for substantial future capital. The significant dilution for legacy shareholders and the complex voting rights of the new preferred stock introduce considerable uncertainty. While the long-term potential is enhanced by the new pipeline and funding, the inherent risks and the early stage of development for all candidates warrant a 'hold' recommendation. Investors should monitor clinical trial progress, regulatory milestones, and further financing needs closely.

Keywords

Biotechnology, Pharmaceutical, SEC Filing, Proxy Statement, Corporate Governance, Redomestication, Cayman Islands, Delaware Corporation, Equity Incentive Plan, Employee Stock Purchase Plan, Capital Raise, PIPE Investment, Damora Therapeutics, Paragon Therapeutics, DMR-001, DMR-002, DMR-003, GB3226, Myeloproliferative Neoplasms (MPNs), Essential Thrombocythemia (ET), Myelofibrosis (MF), Acute Myeloid Leukemia (AML), mutCALR, ENL-YEATS inhibitor, FLT3 inhibitor, Clinical Trials, Preclinical Development, Regulatory Approval, Nasdaq Listing Rules, Shareholder Vote, Dilution, Risk Factors, Financial Reporting, Corporate Restructuring